Synthesis and Anti-Diabetic Evaluation of Some Biuret Derivatives in Streptozotocin-Induced Diabetic Mice
International Pharmacy Acta,
Vol. 8 No. 1 (2025),
6 April 2025
,
Page e6: 1-9
https://doi.org/10.22037/ipa.v8i1.47712
Abstract
The Present study was conducted to examine the anti-diabetic effect of eighteen biuret derivatives in Streptozotocin-induced diabetic mellitus mice. Due to the similarity in chemical structure between biuret derivatives and anti-diabetic drugs such as glibenclamide and metformin, these compounds may exhibit an anti-diabetic effect. In this study, eighteen biuret derivatives were synthesized, and their anti-diabetic effects on streptozotocin-induced diabetic mellitus in male mice were evaluated. Their anti-diabetic effect was compared with glibenclamide, used as a reference agent, and their vehicle after 1, 2, and 4 hours of administration. The results of the present study indicated that these synthesized biuret derivatives need at least two hours to reduce blood glucose. The anti-diabetic effect of these compounds increased with time. There are some relationships between their effects and structures. Among these compounds, which have short (phenyl alkylamine) and (aminoquinaldine) moieties, showed the best activity. In contrast, derivatives with long-chain (phenyl propylamine), (mercaptobenzothiazole), and (phenyl tetrazole) substituents, which lead to more lipophilicity, had no significant hypoglycemic effect. These biuret derivatives can be considered as potential anti-diabetic agents in mice, showing comparable anti-diabetic activity to glibenclamide. Some of them exhibited both dose- and time-dependent effects in mice, similar to glibenclamide.
- Biuret
- Anti-diabetic effect
- Streptozotocin
- Glibenclamide
- Mice
How to Cite
References
Venkatachalapathy, P., et al., Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice. Pharmgenomics Pers Med, 2021. 14: p. 1441-1455.
Ahlqvist, E., R.B. Prasad, and L. Groop, 100 YEARS OF INSULIN: Towards improved precision and a new classification of diabetes mellitus. J Endocrinol, 2021. 252(3): p. R59-R70.
Regnell, S.E. and A. Lernmark, Early prediction of autoimmune (type 1) diabetes. Diabetologia, 2017. 60(8): p. 1370-1381.
Buzzetti, R., S. Zampetti, and E. Maddaloni, Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol, 2017. 13(11): p. 674-686.
Pearson, E.R., et al., Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med, 2006. 355(5): p. 467-77.
Himsworth, H.P., Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. 1936. Int J Epidemiol, 2013. 42(6): p. 1594-8.
Karamanou, M., et al., Milestones in the history of diabetes mellitus: The main contributors. World J Diabetes, 2016. 7(1): p. 1-7.
Bennett, P.H., Basis of the present classification of diabetes. Adv Exp Med Biol, 1985. 189: p. 17-29.
Bottazzo, G.F., A. Florin-Christensen, and D. Doniach, Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet, 1974. 2(7892): p. 1279-83.
Unwin, N., et al., Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med, 2002. 19(9): p. 708-23.
Franks, P.W. and M.I. McCarthy, Exposing the exposures responsible for type 2 diabetes and obesity. Science, 2016. 354(6308): p. 69-73.
Mahajan, A., et al., Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet, 2018. 50(4): p. 559-571.
McColl, J.D., et al., Synthesis and Pharmacological Properties of Phenyl-Substituted Biurets. J Med Chem, 1963. 6: p. 584-7.
Fouladdel, S., et al., Synthesis and cytotoxicity of some biurets against human breast cancer T47D cell line. Bioorg Med Chem Lett, 2010. 20(19): p. 5772-5.
Adibpour, N., et al., Antinociceptive effect of some biuret derivatives on formalin test in mice. Adv Pharm Bull, 2014. 4(2): p. 179-83.
Kajitani, M., et al., Syntheses, antiinflammatory, and analgesic activities of arylbiurets. Arch Pharm (Weinheim), 1990. 323(6): p. 355-9.
Khademvatan, S., et al., In silico and in vitro comparative activity of novel experimental derivatives against Leishmania major and Leishmania infantum promastigotes. Exp Parasitol, 2013. 135(2): p. 208-16.
Kriesel, D.C. and J. Menzie, Synthesis and pharmacological evaluation of some tosylbiurets and tosylthiocarbamates as potential hypoglycemic agents. J Pharm Sci, 1968. 57(10): p. 1791-3.
Hong, G.L., et al., NQO1 Deficiency Aggravates Renal Injury by Dysregulating Vps34/ATG14L Complex during Autophagy Initiation in Diabetic Nephropathy. Antioxidants (Basel), 2021. 10(2).
Abal, P., et al., Characterization of the dinophysistoxin-2 acute oral toxicity in mice to define the Toxicity Equivalency Factor. Food Chem Toxicol, 2017. 102: p. 166-175.
- Abstract Viewed: 106 times
- IPA-2025 Vol8i1-e6 Downloaded: 30 times